Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 48.60% | 23.56% | 3.16% | 36.92% | 8.47% |
| Total Depreciation and Amortization | 21.18% | 22.43% | 13.88% | -101.13% | 31.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | 75.71% | -- |
| Total Other Non-Cash Items | -29.77% | 19.20% | 9.33% | -79.33% | -82.57% |
| Change in Net Operating Assets | -143.64% | -42.93% | -126.84% | 126.88% | 95.88% |
| Cash from Operations | 15.25% | 24.37% | 1.57% | 60.02% | -2.10% |
| Capital Expenditure | 78.26% | 100.00% | 33.33% | 62.16% | -27.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.23% | -33.42% | -- | 20.46% | -- |
| Cash from Investing | 117.65% | -23.59% | -1,235.90% | 23.73% | -1,977.78% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111,950.00% | 4,411.03% | -- | 13,100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 104,550.00% | 11.14% | -43,600.00% | -99.75% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.45% | 106.44% | -8.76% | -117.58% | -762.48% |
